Overview

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Details
Lead Sponsor:
PDL BioPharma, Inc.
Treatments:
Visilizumab